SCHEMBL487116

SCHEMBL487116

O=C(O)COc1ccc(CC2SC(=O)NC2=O)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.75
FFAR1 O14842 9/20 0.64
PPARA Q07869 2/20 0.64
MPC2 O95563 2/20 0.63
CYP2C8 P10632 2/20 0.63
CYP2C9 P11712 2/20 0.63
MAPT P10636 2/20 0.59
CYP3A4 P08684 2/20 0.59
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59
HPGD P15428 1/20 0.59
ALOX15 P16050 1/20 0.59
TSHR P16473 1/20 0.59
KMT2A Q03164 1/20 0.59
HSD17B10 Q99714 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HRH3 Q9Y5N1 1/20 0.58
RXRA P19793 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL14855731 0.95 PPARG (0.69) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL13846966 0.88 CA2 (0.62) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL4221515 0.88 MAOB (0.62) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL1592234 0.88 PPARG (0.70) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL8282053 0.88 PPARG (0.70) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL13846803 0.86 PPARG (0.65) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL19828831 0.86 PPARG (1.00) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL935826 0.86 PPARG (1.00) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL18541499 0.86 PPARG (1.00) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL9570670 0.85 FFAR1 (0.71) PPARGFFAR1PPARAMPC2CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2505587-A1 METHOD FOR MANUFACTURING A 6-SUBSTITUTED-1-METHYL-1H-BENZIMIDAZOLE DERIVATIVE, AND MANUFACTURING INTERMEDIATE FROM SAID METHOD DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-10-03 EP claimed
US-20120238759-A1 METHOD FOR MANUFACTURING A 6-SUBSTITUTED 1-METHYL-1H-BENZIMIDAZOLE DERIVATIVE AND AN INTERMEDIATE OF SAID METHOD DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-09-20 US claimed
US-8106079-B2 Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2012-01-31 US claimed
US-20110092555-A1 Thiazolidinedione compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-21 US claimed
US-20100234612-A1 Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same SANKYO COMPANY, LIMITED (JP) 2010-09-16 US claimed
EP-2226321-A2 Process for producing thiazolidinediones and intermediates thereof Daiichi Sankyo Company, Limited (JP) 2010-09-08 EP claimed
US-20090023929-A1 Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same SANKYO COMPANY, LIMITED (JP) 2009-01-22 US claimed
US-20080103185-A1 Process for Producing Thiazolidinedione Compound and Production Intermediate Thereof DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-05-01 US claimed
EP-1894929-A1 PROCESS FOR PRODUCING THIAZOLIDINEDIONE COMPOUND AND PRODUCTION INTERMEDIATE THEREOF Daiichi Sankyo Company, Limited (JP) 2008-03-05 EP claimed
EP-1798216-A1 INTERMEDIATE OF 6-SUBSTITUTED-1-METHYL-1-H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR PRODUCING SAME Sankyo Company, Limited (JP) 2007-06-20 EP claimed
US-20130183297-A1 METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-18 US disclosed
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE HORIKOSHI, HIROYOSHI (CA) 2013-06-27 US disclosed
EP-2581373-A1 BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE Fujita, Takashi (JP) 2013-04-17 EP disclosed
US-20120263716-A1 METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-10-18 US disclosed
US-20120258991-A1 METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-10-11 US disclosed
WO-2000015638-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2,4-DIONE DERIVATIVES DR. REDDY'S RESEARCH FOUNDATION (IN) 2000-03-23 WO disclosed
EP-0958296-A1 NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-11-24 EP disclosed
US-5985884-A TREATMENT AND/OR PROPHYLAXIS OF DISEASES OR CONDITIONS IN WHICH INSULIN RESISTANCE IS THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISM SUCH AS TYPE II DIABETES, IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDAEMIA, HYPERTENSION, CORONARY HEART DISEASE DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-11-16 US disclosed
WO-1999046279-A2 INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE ENDORECHERCHE, INC. (CA) 1999-09-16 WO disclosed
WO-1997041097-A2 NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES DR. REDDY'S RESEARCH FOUNDATION (IN) 1997-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092555-A1 Thiazolidinedione compound GLP1R, DPP4, KCNK4 PPARG 209/4885FFAR1 2235/4885PPARA 150/4885
US-20120258991-A1 METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG RNASE1, MCL1, EWSR1 PPARG 859/4885FFAR1 3862/4885PPARA 397/4885
US-20120263716-A1 METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD EGFR, ABL1, ERBB2 PPARG 86/4885FFAR1 540/4885PPARA 106/4885
US-20080103185-A1 Process for Producing Thiazolidinedione Compound and Production Intermediate Thereof INSR, GCKR, GPR119 PPARG 28/4885FFAR1 92/4885PPARA 30/4885
US-20090023929-A1 Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same AZI2, CYC1, CCNI PPARG 2224/4885FFAR1 4079/4885PPARA 3420/4885
US-20130183297-A1 METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD EGFR, ABL1, ERBB2 PPARG 86/4885FFAR1 540/4885PPARA 106/4885
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE PPARG, PPARA, PPARD PPARG 1/4885FFAR1 91/4885PPARA 2/4885
US-20120238759-A1 METHOD FOR MANUFACTURING A 6-SUBSTITUTED 1-METHYL-1H-BENZIMIDAZOLE DERIVATIVE AND AN INTERMEDIATE OF SAID METHOD H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, H1-4 PPARG 2583/4885FFAR1 2569/4885PPARA 3695/4885
US-20100234612-A1 Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same CYC1, CYP2B6, COX6B1 PPARG 1752/4885FFAR1 3955/4885PPARA 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.